Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study

Core Viewpoint - Moleculin Biotech, Inc. is advancing its pivotal MIRACLE Study evaluating Annamycin in combination with cytarabine for patients with relapsed or refractory Acute Myeloid Leukemia, with promising results expected from the ongoing clinical trial [3][6]. Company Overview - Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses [5]. - The lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity associated with current treatments [5]. Clinical Development - The MIRACLE Study (MB-108) is an adaptive Phase 3 trial designed with FDA input, involving an initial cohort of 45 patients [3][6]. - The study aims to evaluate the safety and efficacy of Annamycin in combination with cytarabine, with an interim unblinding planned after the initial cohort's treatment completion [3][6]. - The trial builds on positive outcomes from the earlier MB-106 Study, where Annamycin showed overall survival rates exceeding historical benchmarks in a challenging patient population [3]. Additional Pipeline - The company is also developing WP1066, an Immune/Transcription Modulator targeting various cancers, and WP1122, an antimetabolite for potential treatment of pathogenic viruses and certain cancer indications [7].